ArticleLeukemia2017
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Leukemia · 2018Guideline
- Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.Journal of hematology & oncology · 2018Trial
- European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.Blood cancer journal · 2025Article
- Disease Modification in Myelofibrosis: An Elusive Goal?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.Platelets · 2022Article
- Low-dose ruxolitinib shows effective in treating myelofibrosis.Annals of hematology · 2021Article
- A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan.Journal of patient experience · 2021Article
- JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.HemaSphere · 2020Review
- Management of myelofibrosis after ruxolitinib failure.Leukemia & lymphoma · 2020Article
- Management of Myelofibrosis: from Diagnosis to New Target Therapies.Current treatment options in oncology · 2020Review
- The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.Bone marrow transplantation · 2020Review
- Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.Annals of hematology · 2020Article
- Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.British journal of haematology · 2019Article
- MF management.HemaSphere · 2019Article
- [How I treat primary myelofibrosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- [Chinese guideline on the diagnosis and treatment of primary myelofibrosis (2019)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Standard care and investigational drugs in the treatment of myelofibrosis.Drugs in context · 2019Review
- Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.Blood cancer journal · 2018Article
- Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.Wiener klinische Wochenschrift · 2018Article
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.Blood cancer journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 13 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials. However, discordant indications were provided by regulatory agencies and scientific societies for selecting the most appropriate candidates to this drug. The European LeukemiaNet and the Italian Society of Hematology shared the aim of building evidence-based recommendations for the use of ruxolitinib according to the GRADE methodology. Eighteen patient-intervention-comparator-outcome profiles were listed, each of them comparing ruxolitinib to other therapies with the aim of improving one of the three clinical outcomes: (a) splenomegaly, (b) disease-related symptoms, and (c) survival. Ruxolitinib was strongly recommended for improving symptomatic or severe (>15 cm below the costal margin) splenomegaly in patients with an International Prognostic Scoring System (IPSS)/dynamic IPSS risk intermediate 2 or high. Ruxolitinib was also strongly recommended for improving systemic symptoms in patients with an MPN10 score >44, refractory severe itching, unintended weight loss not attributable to other causes or unexplained fever. Because of weak evidence, the panel does not recommend ruxolitinib therapy for improving survival. Also, the recommendations given above do not necessarily apply to patients who are candidates for allogeneic stem cell transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.